777 Service Details:
Service Item
Deliverables
Duration
QC
Construct generation, cloning and plasmid prep all included
3 weeks
A280, Caliper (R/NR) or SDS-PAGE (R/NR), SEC-HPLC, and endotoxin (<0.5 EU/mg) SEC-HPLC
20 mL CHO/HEK293 500 mL CHO/HEK293
2-step purification
1.dx
7.922
100 150 200 250 300 350 400
3 weeks
100-500 mg
Additional QC
RP-HPLC, bioburden, DSF, DSC, SPR, LC/MS, SEC-MALS, peptide mapping, glycan profiling, cIEF, CHO HCP, residual DNA, ELISA, Western blot, freeze thaw study, micro-developability testing
6.911
50
0
0.5 1 1.5 2 2.5 3 3.5
44.555.566.5 7
7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13 13.5 14 14.5 15
Time (min)
Signal:
Name RT (min) 6.911 7.922
Width (min) 0.40 0.33 Sum
Area 23.50
Height 0.79 389.44
Area% 0.28 99.72
Case Study: High-Purity mAb Production Confirmed by SEC-HPLC and Caliper-SDS Data
8365.79 8389.29
In this case, the purity of vanilla antibodies produced in 777 platform showed high purity.
Caliper-SDS
SEC-HPLC
1.dx
Caliper-SDS NR
7.922
100 150 200 250 300 350 400
[Labchip_2021-11-09_18-24-41/A3] 1 NR
99.41
LM % Purity Type
1000 1200
0 200 400 600 800
Xsys
0.59
Xsys
x
6.911
50
0
15
20
25
30
35
40
0.5 1 1.5 2 2.5 3 3.5
44.555.566.5 7
7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13 13.5 14 14.5 15
Aligned Time (sec)
Time (min)
Signal:
Caliper-SDS R
Name RT (min) 6.911 7.922
Width (min) 0.40 0.33 Sum
Area 23.50
Height 0.79 389.44
Area% 0.28 99.72
[Labchip_2021-11-09_18-24-41/E3] 1 Reduce
68.06
% Purity Type
8365.79 8389.29
1000 1200 1400 1600
31.94
LM
400 600 800
Xsys
Caliper-SDS
0 200 -200
Caliper-SDS NR
15
20
25
30
35
40
[Labchip_2021-11-09_18-24-41/A3] 1 NR
Aligned Time (sec)
99.41
LM % Purity Type
1000 1200
0 200 400 600 800
Xsys
0.59
Xsys
x
15
20
25
30
35
40
Aligned Time (sec)
Caliper-SDS R
[Labchip_2021-11-09_18-24-41/E3] 1 Reduce
68.06
% Purity Type
1000 1200 1400 1600
31.94
LM
Learn more: Protein Sciences: HTP Production of High-Quality Vanilla Antibodies
About WuXi Biologics
400 600 800
Xsys
WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore,
0 200 -200
15
20
25
30
35
40
Aligned Time (sec)
and high-quality drug development model.
The world’s leading global single-source platform from concept to commercialization.
wuxibiologics.com | info@wuxibiologics.com
5-9-2024
Powered by FlippingBook